(Q38628257)

4 September 2017

title

Current and advancing treatments for metastatic colorectal cancer (English)

1 reference

4 September 2017

1 reference

Josep Tabernero Caturla

5

1 reference

4 September 2017

Enrique Sanz-Garcia

1

1 reference

4 September 2017

Julieta Grasselli

2

1 reference

4 September 2017

Guillem Argiles

3

1 reference

4 September 2017

M Elena Elez

4

1 reference

4 September 2017

language of work or name

English

0 references

publication date

7 November 2015

1 reference

Expert Opinion on Biological Therapy

4 September 2017

published in

1 reference

4 September 2017

volume

16

1 reference

4 September 2017

issue

1

1 reference

4 September 2017

page(s)

93-110

1 reference

4 September 2017

cites work

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

5-Fluorouracil: mechanisms of action and clinical strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Oxaliplatin: a review in the era of molecularly targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic O

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Vascular-specific growth factors and blood vessel formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Safety of bevacizumab in treating metastatic colorectal cancer: a systematic review and meta-analysis of all randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

VEGF-Trap: a VEGF blocker with potent antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, doubl

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Cetuximab for the treatment of colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic color

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Acquired resistance to EGFR-targeted therapies in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

Prognosis and Therapeutic Implications for Emerging Colorectal Cancer Subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2016.1108405

10.1517/14712598.2016.1108405

21 January 2018

Identifiers

DOI

1 reference

4 September 2017

1 reference